Effect of type oil in treatment of Metabolic syndrome

Evaluating the effect of replacing clarified butter with canola oil on Metabolic Syndrome components, fatty liver index, and insulin resistance in patients with Metabolic Syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170206032417N6

Enrollment

Registered

2023-06-18

Start date

2023-07-06

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome. ????? ????????

Interventions

Initially, individuals will be selected who consume ghee or clarified butter for cooking, with a daily consumption of 3 to 8 units of this oil. In addition to the usual treatment, all individuals will

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having metabolic syndrome according to International Diabetes Federation (IDF) guideline Age range from 35 to 65 years Daily clarified butter/ghee consumption of 3 to 8 servings

Exclusion criteria

Exclusion criteria: Renal disease Heart failure Having various type of cancer Psychotic disorders Pregnancy and lactation during the study

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Measurement of fasting blood sugar at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, IU/ Lit.;Waist circumference. Timepoint: Measurement of waist circumference at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Meter, Cm.;HDL cholesterol. Timepoint: Measurement of HDL cholesterol at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: Measurement of Triglyceride at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, mg/dl.;Systolic blood pressure. Timepoint: Measurement of Systolic blood pressure at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Sphygmomanometer, mm Hg.;Diastolic blood pressure. Timepoint: Measurement of Diastolic blood pressure at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Sphygmomanometer, mm Hg.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Measurement of fasting blood sugar at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, IU/ Lit.;Waist circumference. Timepoint: Measurement of waist circumference at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Meter, Cm.;HDL cholesterol. Timepoint: Measurement of HDL cholesterol at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: Measurement of Triglyceride at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, mg/dl.;Systolic blood pressure. Timepoint: Measurement of Systolic blood pressure at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Sphygmomanometer, mm Hg.;Diastolic blood pressure. Timepoint: Measurement of Diastolic blood pressure at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Sphygmomanometer, mm Hg.

—

Secondary

Measure	Time frame
Weight. Timepoint: Measurement of weight at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Scale. kg.;Body mass index. Timepoint: Measurement of BMI at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Weight(kg)/[height(m)]2 , kg/m2.;Gamma Glutamyl transferase. Timepoint: Measurement of GGT at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method , IU/ Lit.;Serum insulin. Timepoint: Measurement of Serum insulin at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Radioimmunoassay.;Low-density lipoprotein cholesterol. Timepoint: Measurement of LDL at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: Measurement of Total cholesterol at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, mg/dl.;Homeostasis model assessment-insulin resistance. Timepoint: Measurement of HOMA-IR at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: HOMA-IR = [ (Fasting Serum Glucose, mmol/L) × Fasting Serum Insulin, µIU/mL) ] / 22.5.;Height. Timepoint: Measurement of Height at the beginning of the study (before the intervention). Method of measurement: Stadiometer- cm.;Quantitative insulin sensitivity check index. Timepoint: Measurement of QUICKI at the beginning of th	—

Measure

Time frame

Weight. Timepoint: Measurement of weight at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Scale. kg.;Body mass index. Timepoint: Measurement of BMI at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Weight(kg)/[height(m)]2 , kg/m2.;Gamma Glutamyl transferase. Timepoint: Measurement of GGT at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method , IU/ Lit.;Serum insulin. Timepoint: Measurement of Serum insulin at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Radioimmunoassay.;Low-density lipoprotein cholesterol. Timepoint: Measurement of LDL at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: Measurement of Total cholesterol at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: Enzymatic method, mg/dl.;Homeostasis model assessment-insulin resistance. Timepoint: Measurement of HOMA-IR at the beginning of the study (before the intervention) and 12 weeks (after the intervention) after the start of canola oil consumption. Method of measurement: HOMA-IR = [ (Fasting Serum Glucose, mmol/L) × Fasting Serum Insulin, µIU/mL) ] / 22.5.;Height. Timepoint: Measurement of Height at the beginning of the study (before the intervention). Method of measurement: Stadiometer- cm.;Quantitative insulin sensitivity check index. Timepoint: Measurement of QUICKI at the beginning of th

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Alizadeh

Oroumia University of Medical Sciences

alizadeh.m@umsu.ac.ir+98 44 3275 2375

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026